Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM
The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....
ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ALLO-605 for the treatment of adult patients with relapsed or refractory...
FDA Warns of Increased Death Risk for Patients with MM Receiving Melphalan Flufenamide
The OCEAN study evaluating melphalan flufenamide and dexamethasone for the treatment of patients with multiple myeloma (MM) found an increased risk of death, according...
Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
While treatment with ixazomib, lenalidomide, and dexamethasone (ixazomib-Rd) was shown to improve progression-free survival, recent long-term findings from the phase III TOURMALINE-MM1 trial published...
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with...
Deep and Durable Responses Seen With CAR T-Cell Therapy for Pretreated Myeloma
In preliminary efficacy results, treatment with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) led to early, deep, and durable responses in patients with...
Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?
Patients with monoclonal gammopathy of undetermined significance (MGUS) and concomitant non-antibody (Ab)–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple...
Older Patients With Myeloma May Have Suboptimal Response to COVID-19 Vaccination
According to a study published in Blood, older patients with multiple myeloma (MM) experienced reduced efficacy with BNT162b2, Pfizer/BioNTech’s COVID-19 vaccine. However, certain factors...
Tandem High-Dose Influenza Vaccine Offers Durable Seroprotection for Patients With Plasma Cell Dyscrasias
Tandem high-dose influenza vaccination may result in more durable serologic immunity in patients with plasma cell dyscrasias (PCDs), compared with standard vaccination, according to...
Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma
Treatment with the B-cell maturation antigen−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed...
Current Issue
September 2021 Volume 7 Issue 11
This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.